Kendle Further Strengthens Global Clinical Development Operation Through Senior Executive Appointments
Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the promotion of Martha R. Feller, PhD, to Senior Vice President, Global Clinical Development and the appointments of Ubavka M. Denoble, MD, and Judith H. Swilley, PhD, to Vice President and Senior Director, Global Clinical Development – North America, respectively. These appointments strengthen the company's global clinical development leadership team to drive continued growth in its Phase II-III business worldwide. In this newly-created position, Dr. Feller will provide executive leadership for Kendle's Phase II-III operations across five regions, including North America, Europe, Asia/Pacific, Latin America and Africa. Dr. Denoble and Dr. Swilley will provide strategic oversight and direction for the company's Phase II-III clinical development activities in North America, with each responsible for specialized therapeutic and dedicated customer account teams in this region. Dr. Denoble and Dr. Swilley will report to Dr. Feller.
"Phase II-III global clinical development is a core competency for Kendle and an area of important growth opportunity moving forward," said Christopher C. Bergen, President and Chief Operating Officer. "The expanded leadership team announced today strategically positions Kendle to meet significant and continued growth in our Global Clinical Development brand." He continued, "We look forward to leveraging the extensive expertise of Dr. Feller, Dr. Denoble and Dr. Swilley as we focus on providing best-in-class global drug development solutions to meet our customers' multinational needs."
Dr. Feller brings to her new leadership position nearly 30 years of CRO and pharmaceutical industry experience. She most recently was Senior Vice President, Global Clinical Development – North America, a position she has held since joining Kendle in 2004 from Procter & Gamble Pharmaceuticals. Under her leadership, Kendle's North American clinical development operations have delivered consistent and significant growth. Dr. Feller's expertise spans all phases of drug development for both prescription and over-the-counter products across multiple therapeutic areas. She holds a doctorate in biochemistry from the University of Cincinnati College of Medicine.
Dr. Denoble has served as Vice President, Global Safety and Pharmacovigilance, since joining Kendle in 2006 as part of the Charles River Clinical Services acquisition. In this role, she has provided strategic leadership for the global safety function. Dr. Denoble has more than 20 years of CRO and clinical experience, including executive roles in Medical Affairs, Safety/Pharmacovigilance and Clinical Development. She has significant expertise in the ophthalmology and cardiovascular therapeutic areas. Dr. Denoble earned her medical degree from the University of Sarajevo Medical School.
Dr. Swilley has served as a Senior Director, Global Clinical Development – North America since joining Kendle in 2006 as part of the Charles River Clinical Services acquisition. In this role, she provides leadership for Phase II-III projects worldwide. Dr. Swilley has more than 20 years of clinical and training experience in the CRO and pharmaceutical industries, including senior positions in Clinical Monitoring and Staff Training and Development. She has significant expertise in the oncology, infectious disease and dermatology therapeutic areas. Dr. Swilley holds a doctorate in pharmacology from the University of Liverpool.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions — from first-in-human studies through market launch and surveillance — to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions — North America, Europe, Asia/Pacific, Latin America and Africa — to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named "Best Contract Research Organization" in November 2006 by an independent panel for Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
Source: Kendle International Inc.